These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 27009179)

  • 41. Development of a new tuberculosis vaccine: is there value in the mucosal approach?
    Diogo GR; Reljic R
    Immunotherapy; 2014; 6(9):1001-13. PubMed ID: 25341121
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sociodemographic profiling of tuberculosis hotspots in Ethiopia, 2014-2017.
    Gelaw YA; Williams G; Assefa Y; Asressie M; Soares Magalhães RJ
    Trans R Soc Trop Med Hyg; 2019 Jul; 113(7):379-391. PubMed ID: 30989204
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New tuberculosis vaccines.
    Martín Montañés C; Gicquel B
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 1():57-62. PubMed ID: 21420568
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Incorporating patient reporting patterns to evaluate spatially targeted TB interventions.
    Gomes I; Reja M; Shrestha S; Pennington J; Jo Y; Baik Y; Islam S; Khan AH; Faisel AJ; Cordon O; Roy T; Suarez P; Hussain H; Dowdy D
    Ann Epidemiol; 2021 Feb; 54():7-10. PubMed ID: 33166716
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population-level health and economic impacts of introducing Vaccae vaccination in China: a modelling study.
    Mao JJ; Zang X; Yue WL; Zhai PY; Zhang Q; Li CH; Zhuang X; Liu M; Qin G
    BMJ Glob Health; 2023 May; 8(5):. PubMed ID: 37257938
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of tuberculosis control policies using computer simulation.
    Brewer TF; Heymann SJ; Colditz GA; Wilson ME; Auerbach K; Kane D; Fineberg HV
    JAMA; 1996 Dec; 276(23):1898-903. PubMed ID: 8968016
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG?
    Martín C
    Eur Respir J; 2005 Jul; 26(1):162-7. PubMed ID: 15994403
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tuberculosis vaccines--state of the art, and novel approaches to vaccine development.
    da Costa C; Walker B; Bonavia A
    Int J Infect Dis; 2015 Mar; 32():5-12. PubMed ID: 25809749
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pertussis in adolescents and adults: should we vaccinate?
    Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
    Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Should a new tuberculosis vaccine be administered intranasally?
    Källenius G; Pawlowski A; Brandtzaeg P; Svenson S
    Tuberculosis (Edinb); 2007 Jul; 87(4):257-66. PubMed ID: 17321797
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prospects for new TB vaccines: Stop TB Working Group on TB Vaccine Development.
    Fruth U; Young D
    Int J Tuberc Lung Dis; 2004 Jan; 8(1):151-5. PubMed ID: 14974759
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tuberculosis vaccine development at a divide.
    Kaufmann SH
    Curr Opin Pulm Med; 2014 May; 20(3):294-300. PubMed ID: 24626237
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel approaches to tuberculosis prevention: DNA vaccines.
    Rivas-Santiago B; Cervantes-Villagrana AR
    Scand J Infect Dis; 2014 Mar; 46(3):161-8. PubMed ID: 24450840
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New tuberculosis vaccines in India: Modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01
    Clark RA; Weerasuriya CK; Portnoy A; Mukandavire C; Quaife M; Bakker R; Scarponi D; Harris RC; Rade K; Mattoo SK; Tumu D; Menzies NA; White RG
    medRxiv; 2023 Jul; ():. PubMed ID: 36865172
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics.
    Abu-Raddad LJ; Sabatelli L; Achterberg JT; Sugimoto JD; Longini IM; Dye C; Halloran ME
    Proc Natl Acad Sci U S A; 2009 Aug; 106(33):13980-5. PubMed ID: 19666590
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of sex, age & nontuberculous infection at intake on the efficacy of BCG: re-analysis of 15-year data from a double-blind randomized control trial in South India.
    Narayanan PR
    Indian J Med Res; 2006 Feb; 123(2):119-24. PubMed ID: 16575109
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TB vaccine development and the End TB Strategy: importance and current status.
    Fletcher HA; Schrager L
    Trans R Soc Trop Med Hyg; 2016 Apr; 110(4):212-8. PubMed ID: 27076508
    [TBL] [Abstract][Full Text] [Related]  

  • 58. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults.
    Luabeya AK; Kagina BM; Tameris MD; Geldenhuys H; Hoff ST; Shi Z; Kromann I; Hatherill M; Mahomed H; Hanekom WA; Andersen P; Scriba TJ; ; Schoeman E; Krohn C; Day CL; Africa H; Makhethe L; Smit E; Brown Y; Suliman S; Hughes EJ; Bang P; Snowden MA; McClain B; Hussey GD
    Vaccine; 2015 Aug; 33(33):4130-40. PubMed ID: 26095509
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Tuberculosis prevalence survey in Japan].
    Shimao T
    Kekkaku; 2009 Nov; 84(11):713-20. PubMed ID: 19999593
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Heterogeneity of distribution of tuberculosis in Sheka Zone, Ethiopia: drivers and temporal trends.
    Shaweno D; Shaweno T; Trauer JM; Denholm JT; McBryde ES
    Int J Tuberc Lung Dis; 2017 Jan; 21(1):79-85. PubMed ID: 28157469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.